fda import alert green list glp-1 semaglutide tirzepatide 2025 lends a hand to Novo, Lilly on illegal imports September 8, 2025: FDA launches

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors that remains unauthorised by the MHRA and EMA

Retatrutide is a next-generation metabolic medication still undergoing clinical evaluation

Feb 6, 2026 Your doctor hands you a tirzepatide prescription

IL-23i DOSING SKYRIZI Offers the Same Maintenance Schedule and OBI Device, Regardless of Indication or Dosage Strength 1-3 Dosing Schedules for IL-23 Inhibitors in Adults With Moderate to Severe Crohns Disease 1-3 1-3 *Inject 300 mg subcutaneously (given as 2 consecutive injections of 100 mg and 200 mg in any order)